This study is looking at how a medication called Gemtesa affects blood flow in aging women. Researchers want to see if Gemtesa, which targets certain receptors (beta3 adrenergic receptors) in the body, can improve blood vessel function. You might be able to join if you are a healthy woman between 18 and 70 years old, assigned female at birth, and meet specific body mass index (BMI) requirements. You cannot participate if you are pregnant, breastfeeding, or have a history of hormone replacement therapy, certain ovarian conditions, or currently smoke. The main goal is to measure changes in blood flow from the beginning of the study to two minutes after receiving the treatment. The study is currently unclear about its recruitment status and plans to enroll 60 participants.

Study design

This is an interventional study, meaning participants will receive either Gemtesa or a placebo (an inactive pill). It plans to enroll 60 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Blood flow will be measured at two minutes after treatment to assess the primary outcome.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.